[Form 4] Idexx Laboratories Inc Insider Trading Activity

Rhea-AI Filing Summary

Jonathan Jay Mazelsky, who is reported as a Director and the President and CEO of IDEXX Laboratories, reported an insider transaction involving common stock and a related option. The Form 4 shows an acquisition of 183 shares of common stock on 08/08/2025 at a price of $598.488 per share, with reported beneficial ownership following the transaction of 83,494.3016 shares (direct).

The filing also discloses a Premium Incentive Stock Option tied to 183 underlying shares with an exercise/conversion price of $598.488. The explanatory note states the option was granted at a 110% premium to the closing price on February 12, 2021 and became exercisable in one installment on February 14, 2025. The Form 4 is signed by an attorney-in-fact on behalf of Mr. Mazelsky.

Insights

Securities Analyst

TL;DR: Routine insider exercise of a small number of shares by the CEO; transaction appears administrative, not a sale.

The report documents an acquisition of 183 shares at $598.488 per share via a Premium Incentive Stock Option, leaving reported direct beneficial ownership of 83,494.3016 shares. For public-market investors, the absolute size of the transaction is small relative to typical outstanding share counts for large-cap companies, and it is recorded as an acquisition rather than a disposition. The explanatory note clarifies the option grant terms (110% premium to the Feb 12, 2021 closing price) and exercisability in one installment on Feb 14, 2025. This appears to be a routine exercise of executive stock compensation rather than an indicator of change in control or liquidity event.

Corporate Governance Expert

TL;DR: Insider exercise aligns with longstanding equity compensation; governance implications are limited absent additional transactions.

Mr. Mazelsky is listed as both Director and President and CEO, and the Form 4 documents exercise-related activity for a Premium Incentive Stock Option covering 183 shares at an exercise price of $598.488. The explanatory language discloses the original grant premium and the single-installment exercisability date, indicating standard executive award mechanics. No sales or transfers are reported here, and the form shows direct ownership post-transaction. From a governance perspective, this filing documents execution of compensation rights rather than compensation policy changes or related-party arrangements that would warrant heightened scrutiny.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MAZELSKY JONATHAN JAY

(Last) (First) (Middle)

ONE IDEXX DRIVE

(Street)

WESTBROOK ME 04092

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IDEXX LABORATORIES INC /DE [ IDXX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
08/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/08/2025		M		183	A	$598.488	83,494.3016	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Premium Incentive Stock Option (right-to-buy)	$598.488	08/08/2025		M			183	(1)	02/13/2031	Common Stock	183	(2)	0	D

Explanation of Responses:

1. Grant of option at a 110% premium to the closing price of Issuer common stock on the Nasdaq Global Select Market on February 12, 2021 to buy shares of Issuer common stock that became exercisable in one installment on February 14, 2025.

2. Not applicable.

Remarks:

	/s/ Lily J. Lu, Attorney-in-Fact for Jonathan Jay Mazelsky	08/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 for IDEXX (IDXX)?

The Form 4 was filed on behalf of Jonathan Jay Mazelsky, who is reported as a Director and President and CEO of IDEXX Laboratories.

What transaction is reported on the Form 4 for IDXX?

The filing reports an acquisition of 183 shares of common stock on 08/08/2025 at a price of $598.488 per share.

How many shares did Mr. Mazelsky beneficially own after the reported transaction?

The Form 4 reports 83,494.3016 shares beneficially owned following the reported transaction, held directly.

Was a derivative security involved in the transaction?

Yes. The filing discloses a Premium Incentive Stock Option with an exercise/conversion price of $598.488 covering 183 underlying shares.

When did the option become exercisable according to the filing?

The explanatory note states the option became exercisable in one installment on February 14, 2025 and was granted at a 110% premium to the closing price on February 12, 2021.

Who signed the Form 4 on behalf of Mr. Mazelsky?

The Form 4 is signed by Lily J. Lu, Attorney-in-Fact for Jonathan Jay Mazelsky.